Jefferies Group's SABS Position Overview
Jefferies Group (via Jefferies Financial Group Inc.) currently holds 903,094 shares of SAB Biotherapeutics, Inc. (SABS) worth $3.46 M, representing 0.02% of the portfolio. First purchased in 2025-Q4, this recently established position has been held for 2 quarters.
Based on recent 13F filings, Jefferies Group has initiated a new position in SABS, representing a fresh investment thesis on this company. Largest addition occurred in Q1 2026, adding 322,766 shares.
Analysis based on 13F filings available since 2013 Q2
Jefferies Group's SAB Biotherapeutics (SABS) Holding Value Over Time
Track share changes against reported price movement
Quarterly SAB Biotherapeutics (SABS) Trades by Jefferies Group
| Report Date | Bought/Sold (Sh.) | % Change | Qtr. End Shares | Reported Price |
|---|---|---|---|---|
| Q1 2026 | +322,766 | Add 55.62% | 903,094 | $3.83 |
| Q4 2025 | +580,328 | New Buy | 580,328 | $3.74 |
Jefferies Group's SAB Biotherapeutics Investment FAQs
Jefferies Group first purchased SAB Biotherapeutics, Inc. (SABS) in Q4 2025, acquiring 580,328 shares, as reported in their 13F filing for that period. Note: Analysis reflects filings available since Q2 2013; earlier records may be incomplete.
Jefferies Group has held SAB Biotherapeutics, Inc. (SABS) for 2 quarters since Q4 2025.
Jefferies Group's largest addition to SAB Biotherapeutics, Inc. (SABS) was in Q4 2025, adding 580,328 shares worth $2.17 M.
According to the latest 13F filing for Q1 2026, Jefferies Group's firm, Jefferies Financial Group Inc., owns 903,094 shares of SAB Biotherapeutics, Inc. (SABS), valued at approximately $3.46 M.
As of the Q1 2026 filing, SAB Biotherapeutics, Inc. (SABS) represents approximately 0.02% of Jefferies Group's publicly disclosed stock portfolio, making it one of their key holdings.
Jefferies Group's peak holding in SAB Biotherapeutics, Inc. (SABS) was 903,094 shares, as reported at the end of Q1 2026.